Form 4: Bolt Biotherapeutics COO Grant Yonehiro Acquires 350,000 Stock Options

Grant Yonehiro, Chief Operating Officer of Bolt Biotherapeutics, acquired 350,000 stock options on May 1, 2025, according to a Form 4 filing with the SEC.

Summary

• Grant Yonehiro, the Chief Operating Officer of Bolt Biotherapeutics, acquired 350,000 stock options on May 1, 2025.
• The options have an exercise price of $0.351.
• The options vest monthly, with 1/36th of the shares vesting each month following January 1, 2025, contingent upon continuous service to the Issuer.
• The options expire on April 30, 2035.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates continued commitment from a key executive.

Positives

• The acquisition of stock options by the COO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies a continued service commitment from the COO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in biotech companies.
• The size of the grant and the vesting schedule are generally aligned with industry standards for companies of similar size and stage of development.
• Comparable companies such as Xencor or Iovance Biotherapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant aligns the COO's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates

Keywords

stock options, Form 4, Bolt Biotherapeutics, Grant Yonehiro, COO, acquisition, vesting